Where is Juniper located?

Juniper is headquartered in Bridgewater, United States.

Is Juniper a funded company?

Juniper is a funded company, having raised a total of $***** in its 1st and only funding round, a Seed round on Dec 01, 2025.

When was the latest funding round of Juniper?

Juniper's latest funding was a $***** Seed round on Dec 01, 2025, with participation from 1 investor. Its primary sector is Oncology. In United States, the Oncology sector has seen $2.37B in funding in 2026 to date.

Where does Juniper rank among its competitors?

Juniper ranks 1830th amongst 2507 active competitors, of which 872 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Immuneel, which secured $10.5M in Jun, 2026.

Who are the top competitors of Juniper?

Juniper's top competitors include Jazz Pharmaceuticals, Sana Biotechnology and Ideaya Biosciences. Among them, Immuneel secured the most recent funding round in June, 2026.

Juniper - 2026 Company Profile, Funding & Competitors

Juniper is a seed company based in Bridgewater (United States). It operates as a Developer of radiopharmaceutical agents for diagnostic and therapeutic applications in medicine. Juniper has raised $40M in funding from Novacapital. The company has 2507 active competitors, including 872 funded and 619 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, Sana Biotechnology and Ideaya Biosciences.

Company Details

Developer of radiopharmaceutical agents for diagnostic and therapeutic applications in medicine. The company focuses on combining radioisotopes with ligands to diagnose diseases earlier. It aims to treat diseases more effectively while minimizing side effects. The company is advancing a pipeline of radiopharmaceutical agents across multiple disease states.

Key Metrics

Location

Bridgewater, United States

Stage

Seed

Total Funding

$40M in 1 round

Latest Funding Round

Seed, Dec 01, 2025, $*****

Investors

Novacapital

Ranked

1830^th among 2507 active competitors

Similar Companies

Molecular Partners & 95 more

View Juniper's full profile

Juniper has raised a total funding of $40M over 1 round. Its latest funding round was a Seed round on Dec 01, 2025 for $*****. 1 investor participated in its latest round. Juniper has 1 institutional investor.

Here is the list of recent funding rounds of Juniper:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Dec 01, 2025	9329079	Seed	5226414	2410793	4840956	2587233

Access funding benchmarks and valuations. Sign up today!

View details of Juniper's funding rounds and investors

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Juniper include Jazz Pharmaceuticals, Sana Biotechnology and Ideaya Biosciences. Here is the list of Top 10 competitors of Juniper, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	82/100
2nd	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating various human diseases	$821M	Baillie Gifford, Google Ventures & 17 others	75/100
3rd	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	BVF Partners, Boxer Capital & 15 others	72/100
4th	Sutro Biopharma 2003, United States, Public	Developer of antibody-based therapeutics for cancer therapy	$175M	Skyline Ventures, SV Health Investors & 17 others	72/100
5th	Syndax 2005, Waltham (United States), Public	Developer of targeted therapies for the treatment of cancer	$198M	Fidelity Investments, Domain Associates & 19 others	72/100
6th	Karyopharm 2008, Newton (United States), Public	Biopharmaceutical company focused on developing and commercializing innovative cancer therapies	$98.4M	Foresite Capital, Avidity Partners & 16 others	71/100
7th	C4 Therapeutics 2016, Cambridge (United States), Public	Developer of small molecule drugs for treating cancer	$223M	Cobro Ventures, Perceptive Advisors & 27 others	71/100
8th	Immuneel 2018, Bengaluru (India), Series B	Developer of T-cell therapies for the treatment of cancer	$49.8M	True North, Eight Roads Ventures & 23 others	71/100
9th	Zymeworks 2003, Vancouver (Canada), Public	Developer of bi-specific antibodies & antibody-drug conjugates to treat cancer	$146M	CTI Life Sciences Fund, Advanced Biotechnologies Venture Fund ... & 17 others	71/100
10th	Harbour BioMed 2016, Shanghai (China), Public	Developer of antibody therapeutics in immunology and oncology disease	$313M	GIC, Hudson Bay Capital & 19 others	71/100
1830th	Juniper Bridgewater (United States), Seed	Developer of radiopharmaceutical agents for diagnostic and therapeutic applications in medicine	$40M	Novacapital	25/100